Revive Therapeutics is a life sciences company that aims to develop psychedelics and cannabinoids for rare disorders and infectious diseases.
Revive Therapeutics
The company has bought the intellectual property from PharmaTher and has acquired Psilocybin Pharma Corporation.
Revive Therapeutics has raised a total of $18.4 million US in funding over 1 round. This was a Post-IPO Equity round raised on Feb 12, 2021.
Revive are listed on the TSXV under the ticker RVV.
Note: The information about this company is still sparse.
Key Staff
- Michael Frank – Chairman & CEO
- Carmelo Marrelli – CFO
- Kelly McKee – CSO (Consultant)
News
- Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program (press release, December 2020)
- Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder (press release, September 2020)
- Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics (press release, August 2020)
Activities
B2B
B2C
Biotech
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Revive Therapeutics Ltd. (OTCMKTS: RVVTF) Included in Inaugural PSIL ETF launch and Offers Bucillamine Study Updates (, 18 April 2024)Revive Therapeutics Inc. (OTCMKTS: RVVTF) Signs Psilocybin Research Partnership Agreement With PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) (, 24 November 2021)